Skip to main content

89bio, Inc.

ETNBDelisted Oct 30, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001785173

89bio, Inc. was delisted on Oct 30, 2025; its insiders filed their last Form 4 on Nov 3, 2025; 198 institutions reported holding it in 13F filings for Q3 2025, worth $2.27B in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by 89bio, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for 89bio, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for 89bio, Inc.
NameTitleLast reported holdingLast filingFilings, past year
RA Capital Healthcare Fund LPDirector, 10% Owner0IndirectNov 3, 20251
Ra Capital Management, L.P.Director, 10% Owner0IndirectNov 3, 20251
Kolchinsky PeterDirector, 10% Owner0IndirectNov 3, 20251
Shah Rajeev M.Director, 10% Owner0IndirectNov 3, 20251
RA Capital Nexus Fund, L.P.Director, 10% Owner0IndirectNov 3, 20251
Laporte KathleenDirector0Oct 30, 20251
Zoth Lota S.Director–Oct 30, 20251
Mansbach Harry HChief Medical Officer0Oct 30, 20251
Hayden Michael RDirector0IndirectOct 30, 20251
Palekar RohanChief Executive Officer0Oct 30, 20251
Sarena Francis WillardChief Operating Officer0Oct 30, 20251
Babler MartinDirector–Oct 30, 20251
Altschuler StevenDirector–Oct 30, 20251
McWherter CharlesDirector0Oct 30, 20251
Martins RyanChief Financial Officer0Oct 30, 20252
DiRocco DerekDirector–Oct 30, 20251
Le-Nguyen QuocSee Remarks0IndirectOct 30, 20251
Atkinson Edward Morrow IIIDirector0Oct 30, 20251
Grunberg GregoryDirector, 10% Owner–Feb 13, 20230
Waisbourd RamSee Remarks8,750Feb 22, 20220
OrbiMed Advisors LLC10% Owner1,829,436IndirectJan 27, 20220
OrbiMed Israel GP II, L.P.10% Owner1,829,436IndirectJan 27, 20220
OrbiMed Advisors Israel II Ltd10% Owner1,829,436IndirectJan 27, 20220
OrbiMed Capital GP VI LLC10% Owner1,829,436IndirectJan 27, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 17, 2025 (view filing)Jul 152 daysLe-Nguyen QuocSee RemarksSSale−10.5K$11.02−$115.3K−3.3%309.4K after10b5-1
Apr 17, 2025 (view filing)Apr 152 daysLe-Nguyen QuocSee RemarksSSale−15.3K$5.95−$91.2K−4.5%328.3K after10b5-1
Feb 3, 2025 (view filing)5:38 PM ETJan 304 daysRA Capital Healthcare Fund LP and 4 othersDirector, 10% OwnerPPurchase+5.71M$8.75+$50.0M+41.3%19.6M after
Jan 23, 2025 (view filing)Jan 21-222 daysMcWherter CharlesDirectorPPurchase+15.0K$6.66+$99.8K+150.0%25.0K after2 lots
Jan 17, 2025 (view filing)Jan 152 daysLe-Nguyen QuocSee RemarksSSale−11.0K$6.49−$71.1K−3.9%271.8K after10b5-1
Dec 10, 2024 (view filing)Dec 64 daysPalekar RohanChief Executive OfficerPPurchase+5.00K$7.89+$39.5K+1.1%471.2K after
Dec 9, 2024 (view filing)Dec 54 daysMcWherter CharlesDirectorPPurchase+10.0K$8.00+$80.0KNew position10.0K after
Nov 25, 2024 (view filing)Nov 223 daysPalekar RohanChief Executive OfficerPPurchase+10.0K$8.35+$83.5K+2.2%466.2K after
Nov 18, 2024 (view filing)8:13 PM ETNov 144 daysRA Capital Healthcare Fund LP and 4 othersDirector, 10% OwnerPPurchase+3.25M$8.50+$27.6M–4.33M afterDerivative
Nov 1, 2024 (view filing)Oct 302 daysLe-Nguyen QuocSee RemarksSSale−28.0K$8.12−$227.0K−13.0%187.8K after10b5-1
Apr 3, 2024 (view filing)Apr 12 daysPalekar RohanChief Executive OfficerSSale−52.7K$10.91−$575.2K−10.3%459.2K after10b5-1
Mar 6, 2024 (view filing)5:40 PM ETMar 42 daysRA Capital Healthcare Fund LP and 4 othersDirector, 10% OwnerPPurchase+1.35M$15.35+$20.7M+12.2%12.4M after
Feb 28, 2024 (view filing)Feb 262 daysPalekar RohanChief Executive OfficerSSale−4.48K$10.76−$48.2K−0.9%486.9K after10b5-1
Jan 3, 2024 (view filing)Dec 29, 20235 daysPalekar RohanChief Executive OfficerSSale−50.0K$11.20−$560.0K−14.2%301.2K after10b5-1
Dec 13, 2023 (view filing)4:31 PM ETDec 112 daysRA Capital Healthcare Fund LP and 4 othersDirector, 10% OwnerPPurchase+1.08M$9.25+$10.0M–1.08M afterDerivative
Jul 18, 2023 (view filing)Jul 171 dayLaporte KathleenDirectorSSale−12.5K$18.80−$235.0K−100.0%0 after
Jun 7, 2023 (view filing)Jun 52 daysPalekar RohanChief Executive OfficerSSale−15.0K$20.00−$300.0K−5.0%287.0K after
Jun 5, 2023 (view filing)Jun 14 daysAtkinson Edward Morrow IIIDirectorSSale−6.25K$17.91−$111.9K−100.0%0 after
May 11, 2023 (view filing)May 92 daysLe-Nguyen QuocSee RemarksSSale−13.7K$18.11−$247.8K−7.7%165.0K after
Apr 6, 2023 (view filing)Apr 42 daysMartins RyanChief Financial OfficerSSale−8.72K$14.95−$130.4K−14.0%53.6K after
Mar 30, 2023 (view filing)5:00 PM ETMar 246 daysLateRA Capital Healthcare Fund LP and 4 othersDirector, 10% OwnerPPurchase+2.46M$16.25+$40.0M+28.6%11.1M after
Mar 30, 2023 (view filing)Mar 30, 2022-Mar 28, 2023365 daysLateHayden Michael RDirectorPPurchase+87.8K$12.28+$1.08MNew position61.5K after4 lots
Mar 27, 2023 (view filing)Mar 234 daysMartins RyanChief Financial OfficerSSale−5.00K$16.11−$80.5K−8.5%53.6K after
Mar 27, 2023 (view filing)Mar 234 daysPalekar RohanChief Executive OfficerSSale−15.0K$16.00−$240.0K−5.3%269.1K after
Mar 3, 2023 (view filing)Mar 12 daysAtkinson Edward Morrow IIIDirectorSSale−10.0K$13.60−$136.0K−100.0%0 after
Feb 22, 2023 (view filing)Feb 211 dayMartins RyanChief Financial OfficerSSale−2.54K$13.89−$35.3K−4.2%58.6K after
Feb 10, 2023 (view filing)Feb 82 daysMartins RyanChief Financial OfficerSSale−1.48K$14.41−$21.3K−4.3%32.9K after
Feb 7, 2023 (view filing)Feb 34 daysMartins RyanChief Financial OfficerSSale−3.59K$13.04−$46.8K−9.2%35.4K after2 lots
Jan 5, 2023 (view filing)Jan 32 daysMartins RyanChief Financial OfficerSSale−5.95K$12.51−$74.4K−14.1%36.4K after
Oct 20, 2022 (view filing)5:28 PM ETOct 182 daysRA Capital Healthcare Fund LP and 4 othersDirector, 10% OwnerPPurchase+1.17M$7.65+$8.97M+15.1%8.96M after
Jul 6, 2022 (view filing)5:27 PM ETJul 15 daysRA Capital Healthcare Fund LP and 4 othersDirector, 10% OwnerPPurchase+2.82M$3.55+$10.0M+56.7%7.78M after
Jul 6, 2022 (view filing)5:27 PM ETJul 15 daysRA Capital Healthcare Fund LP and 4 othersDirector, 10% OwnerPPurchase+1.41M$0.002+$2.82K–1.41M afterDerivative
Feb 3, 2022 (view filing)Feb 12 daysWaisbourd RamSee RemarksSSale−7.00K$5.70−$39.9K−100.0%0 after
Jan 31, 2022 (view filing)Jan 27-284 daysPalekar RohanChief Executive OfficerPPurchase+7.50K$7.05+$52.9K+19.6%45.8K after2 lots
Jan 27, 2022 (view filing)5:22 PM ETJan 25-262 daysOrbiMed Advisors LLC and 3 others10% OwnerSSale−70.6K$8.39−$592.4K−3.7%1.83M after4 lots
Dec 20, 2021 (view filing)Dec 164 daysWaisbourd RamSee RemarksSSale−7.00K$11.48−$80.4K−100.0%0 after
Nov 18, 2021 (view filing)Nov 162 daysWaisbourd RamSee RemarksSSale−7.00K$16.49−$115.4K−100.0%0 after
Oct 20, 2021 (view filing)Oct 182 daysWaisbourd RamSee RemarksSSale−7.00K$17.49−$122.4K−100.0%0 after
Sep 20, 2021 (view filing)Sep 164 daysWaisbourd RamSee RemarksSSale−7.00K$19.46−$136.2K−100.0%0 after
Aug 18, 2021 (view filing)Aug 162 daysWaisbourd RamSee RemarksSSale−7.00K$18.28−$128.0K−100.0%0 after
Jul 19, 2021 (view filing)Jul 163 daysWaisbourd RamSee RemarksSSale−7.00K$16.80−$117.6K−100.0%0 after
Jul 8, 2021 (view filing)Jul 7-81 dayPalekar RohanChief Executive OfficerPPurchase+7.00K$16.84+$117.8K+23.3%37.0K after2 lots